Progenics Pharmaceuticals (PGNX) Releases Earnings Results, Misses Expectations By $-0.06 EPS

Progenics Pharmaceuticals (PGNX) reported quarterly earnings results on Thursday, May-5-2016. The company reported $-0.18 earnings per share for the quarter, missing the analyst consensus estimate by $-0.06. Analysts had a consensus of $-0.12. The company posted revenue of $2.50 million in the period, compared to analysts expectations of $3.76 million. The company’s revenue was up 908.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.15 EPS.

Progenics Pharmaceuticals closed down -0.18 points or -3.35% at $5.19 with 10,12,226 shares getting traded on Wednesday. Post opening the session at $5.29, the shares hit an intraday low of $5.19 and an intraday high of $5.45 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

In a different news, on Apr 22, 2016, Paul J Maddon (director) purchased 5,000 shares at $4.90 per share price. According to the SEC, on Jun 15, 2015, Robert J Israel (Executive Vice President, Medi) sold 2,000 shares at $6.83 per share price.

Progenics Pharmaceuticals engaged in developing medicines for oncology. The Company completed Phase II clinical trials of two product candidates for prostate cancer and resumed a pivotal Phase II trial of an ultra-orphan radiotherapy candidate for pheochromocytoma. Its principal clinical-stage product candidates in oncology are PSMA ADC 1404 (trofolastat) and Azedra. PSMA ADC is a human monoclonal antibody-drug conjugate designed to deliver a chemotherapeutic agent to cancer cells by targeting the three-dimensional structure of the PSMA protein. 1404 (trofolastat) is a radio-labeled small molecule which binds PSMA and acts as an imaging agent to diagnose and detect prostate cancer. Azedra is a radiotherapeutic product candidate in development as a treatment for pheochromocytoma a rare tumor found in the adrenal glands and related paraganglioma tumors occurring in other tissues. The Company also commercializes Relistor a cure for opioid-induced constipation (OIC).

Progenics Pharmaceuticals

Leave a Reply

Progenics Pharmaceuticals - Is it time to Sell?

Top Brokerage Firms are advising their investors on Progenics Pharmaceuticals. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.